Rice Hall James & Associates LLC Sells 2,911 Shares of Zynex, Inc. (NASDAQ:ZYXI)

Rice Hall James & Associates LLC decreased its position in Zynex, Inc. (NASDAQ:ZYXI) by 1.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 230,678 shares of the company’s stock after selling 2,911 shares during the quarter. Rice Hall James & Associates LLC owned 0.72% of Zynex worth $1,882,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Renaissance Technologies LLC increased its position in shares of Zynex by 68.7% during the 2nd quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock valued at $1,769,000 after purchasing an additional 77,300 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Zynex by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 1,187,089 shares of the company’s stock valued at $14,684,000 after purchasing an additional 6,097 shares during the last quarter. Millennium Management LLC increased its position in shares of Zynex by 66.5% during the 2nd quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock valued at $2,769,000 after purchasing an additional 118,615 shares during the last quarter. Quest Partners LLC increased its position in shares of Zynex by 646.7% during the 2nd quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock valued at $120,000 after purchasing an additional 11,195 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System bought a new position in shares of Zynex during the 1st quarter valued at approximately $137,000. Institutional investors own 29.68% of the company’s stock.

Zynex Price Performance

Shares of ZYXI stock opened at $8.76 on Friday. Zynex, Inc. has a twelve month low of $7.15 and a twelve month high of $13.77. The stock has a market capitalization of $279.01 million, a price-to-earnings ratio of 58.40 and a beta of 0.53. The stock has a fifty day simple moving average of $8.11 and a two-hundred day simple moving average of $9.09. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66.

Zynex (NASDAQ:ZYXI) last issued its quarterly earnings data on Thursday, October 24th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. The firm had revenue of $49.97 million during the quarter, compared to analysts’ expectations of $50.83 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The firm’s quarterly revenue was up .1% on a year-over-year basis. During the same period in the prior year, the business posted $0.10 EPS. On average, analysts predict that Zynex, Inc. will post 0.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ZYXI. Royal Bank of Canada cut their price objective on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. HC Wainwright upped their price objective on Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, October 25th.

Insider Buying and Selling

In related news, COO Anna Lucsok sold 8,083 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $8.03, for a total transaction of $64,906.49. Following the transaction, the chief operating officer now directly owns 16,980 shares of the company’s stock, valued at $136,349.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders sold 12,083 shares of company stock worth $100,006 in the last three months. 52.13% of the stock is owned by insiders.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.